Related Experiment Video
Updated: Nov 27, 2025
Quantitative FRET Förster Resonance Energy Transfer Analysis for SENP1 Protease Kinetics Determination
Published on: February 21, 2013
Identification of a Selective RelA Inhibitor Based on DSE-FRET Screening Methods
Yoshitomo Shiroma1, Go Fujita1, Takuya Yamamoto1
1Department of Cellular and Molecular Biology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8553, Japan.
Abstract:
Nuclear factor-κB (NF-κB) is an important transcription factor involved in various biological functions, including tumorigenesis. Hence, NF-κB has attracted attention as a target factor for cancer treatment, leading to the development of several inhibitors. However, existing NF-κB inhibitors do not discriminate between its subunits, namely, RelA, RelB, cRel, p50, and p52. Conventional methods used to evaluate interactions between transcription factors and DNA, such as electrophoretic mobility shift assay and luciferase assays, are unsuitable for high-throughput screening (HTS) and cannot distinguish NF-κB subunits. We developed a HTS method named DNA strand exchange fluorescence resonance energy transfer (DSE-FRET). This assay is suitable for HTS and can discriminate a NF-κB subunit. Using DSE-FRET, we searched for RelA-specific inhibitors and verified RelA inhibition for 32,955 compounds. The compound A55 (2-(3-carbamoyl-6-hydroxy-4-methyl-2-oxopyridin-1(2H)-yl) acetic acid) selectively inhibited RelA-DNA binding. We propose that A55 is a seed compound for RelA-specific inhibition and could be used in clinical applications.
Insights
Researchers developed a novel high-throughput screening method to identify specific inhibitors for the RelA subunit of nuclear factor-κB (NF-κB). Compound A55 was found to selectively inhibit RelA-DNA binding, offering potential for targeted cancer therapies.
Area of Science:
- Molecular Biology
- Biochemistry
- Cancer Research
Background:
- Nuclear factor-κB (NF-κB) is a crucial transcription factor implicated in tumorigenesis.
- Existing NF-κB inhibitors lack specificity, targeting multiple subunits (RelA, RelB, cRel, p50, p52).
- Conventional assays for transcription factor-DNA interactions are not high-throughput and cannot distinguish NF-κB subunits.
Purpose of the Study:
- To develop a high-throughput screening (HTS) method capable of discriminating NF-κB subunits.
- To identify specific inhibitors of the RelA subunit of NF-κB.
- To evaluate the potential of identified inhibitors for clinical applications in cancer treatment.
Main Methods:
- Development of a novel DNA strand exchange fluorescence resonance energy transfer (DSE-FRET) assay for HTS.
- Screening of 32,955 compounds using the DSE-FRET assay to find RelA-specific inhibitors.
- Verification of RelA inhibition by the identified compounds.
Main Results:
- The DSE-FRET assay proved suitable for HTS and capable of discriminating NF-κB subunits.
- 32,955 compounds were screened, leading to the identification of potential RelA inhibitors.
- Compound A55 (2-(3-carbamoyl-6-hydroxy-4-methyl-2-oxopyridin-1(2H)-yl) acetic acid) was identified as a selective inhibitor of RelA-DNA binding.
Conclusions:
- The DSE-FRET assay is a valuable tool for developing subunit-specific NF-κB inhibitors.
- Compound A55 serves as a promising seed compound for developing RelA-specific cancer therapeutics.
- Targeted inhibition of RelA may offer a more effective strategy for cancer treatment.
